News & Updates

Intention-to-treat (ITT) SGLT2 inhibitor (SGLTi) use was associated with reduced risk of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (APRI) failure, according to findings of a population-based study in Hong Kong.

In patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) refractory to immune checkpoint inhibitor (ICI) therapy, the combination of liposomal irinotecan plus nimotuzumab yields meaningful clinical activity while having favourable tolerability, as shown in a phase II study.

For vulnerable cancer patients undergoing chemotherapy, treatment with low-dose olanzapine works just as well as megestrol acetate in terms of promoting appetite and weight gain, as shown in a study.

Nonmetastatic breast cancer survivors who are genetically predisposed to having an excess body weight appear to be at increased risk of mortality, as shown in a study.

Sentinel lymph node biopsy (SLNB) may be safely omitted after breast-conserving therapy in patients with early-stage, node-negative breast cancer, with 5-year data from the BOOG 13-08 trial showing no difference in regional recurrence-free and distant disease-free survival outcomes whether or not SLNB was performed.

A recent study has shown the capacity of a novel prognostic model in predicting the long-term risk for prostate cancer-specific mortality (PCSM) following a prostate-specific antigen (PSA) test.